Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common drug stop infections before they start?

NCT ID NCT07054320

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether the drug rapamycin (sirolimus) can help prevent infections or make them less severe. Fifteen adults will take the drug for 6 months while researchers monitor their health through blood tests, heart checks, and surveys. The goal is to see if rapamycin is safe and effective for reducing infection-related illness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male and female adults, 18 years and older

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female Adults, 18 years and older * Females of child-bearing age taking birth control medication * Received a Hoskinson Health and Wellness Clinic physician prescription for Rapamune (Sirolimus) Exclusion Criteria: * Adults requiring monoclonal antibody or biological treatment * Adults diagnosed with an acute lower respiratory or GI infection within 2 weeks * Adults females who are not taking birth control medication, are pregnant or nursing mothers * Adults reporting severe mental or physical disability * Adults reporting unwillingness to travel to onsite clinical facilities * Adults with any change in chronic disease symptoms or medication within 3 months * Any contraindications to medical treatment with Rapamune (Sirolimus), as outlined in the FDA-approved medication guide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infectious diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hoskinson Health and Wellness Clinic

    Gillette, Wyoming, 82718, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.